TOKYO, Dec 18 (Reuters) - Japan’s Shionogi & Co said on Tuesday that it has applied to health regulators in the United States, Canada and Europe for approval of its HIV drug Dolutegravir. Shionogi developed Dolutegravir with a Viiv Healthcare, an AIDS drug joint venture between GlaxoSmithKline and Pfizer, in exchange for its rights to the drug.
the company's primary goal is to help sick people
( z1 goal :mod ( z2 primary ) :poss ( z3 company ) :domain ( z4 help :ARG0 z3 :ARG1 ( z5 person :ARG1-of ( z6 sick ) ) ) )